Save your place

Sign in to WhoBought

Please try again later.

Enliven Therapeutics, Inc. (ELVN) institutional ownership

Latest close $52.85 Jul 22, 2026
Market cap$1.1B 52-week range SectorHealthcare
Funds holding · Q1 2026
171
reported ELVN position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
120 buyers · 51 sellers

Enliven Therapeutics, Inc. (ELVN) price and institutional activity

Dates

Q1 2026

$0 bought by 120 investors
Bellevue Group AGPolar Capital Holdings PLC +118 more
$0 sold by 51 investors
Fairmount Funds Management LLCJanus Henderson Group PLC +49 more
Bought Sold Totals per quarter; hover a bar for the names.

Enliven Therapeutics, Inc. (ELVN) institutional activity · 171

Investor Type Est. change Change Δ Own Date
Bellevue Group AG · New
Change +2.3M Date Q1 2026
Bellevue Group AG New· Q1 2026 +2.3M Q1 2026
Fairmount Funds Management LLC · Reduced
Change −1.9M Date Q1 2026
Fairmount Funds Management LLC Reduced· Q1 2026 −1.9M Q1 2026
Janus Henderson Group PLC · Reduced
Change −1.7M Date Q1 2026
Janus Henderson Group PLC Reduced· Q1 2026 −1.7M Q1 2026
Polar Capital Holdings PLC · Added
Change +1.6M Date Q1 2026
Polar Capital Holdings PLC Added· Q1 2026 +1.6M Q1 2026
Point72 Asset Management, L.P. · Exited
Change −1.5M Δ Own −100.0% Date Q1 2026
Point72 Asset Management, L.P. Exited· Q1 2026 −1.5M −100.0% Q1 2026
Venrock Adviser, LLC · Reduced
Change −1.5M Date Q1 2026
Venrock Adviser, LLC Reduced· Q1 2026 −1.5M Q1 2026
Commodore Capital LP · Reduced
Change −1.4M Date Q1 2026
Commodore Capital LP Reduced· Q1 2026 −1.4M Q1 2026
Capital Research Global Investors · Exited
Change −1.3M Δ Own −100.0% Date Q1 2026
Capital Research Global Investors Exited· Q1 2026 −1.3M −100.0% Q1 2026
Blackstone Inc. · Exited
Change −955K Δ Own −100.0% Date Q1 2026
Blackstone Inc. Exited· Q1 2026 −955K −100.0% Q1 2026
Soleus Capital Management, L.P. · Reduced
Change −794K Date Q1 2026
Soleus Capital Management, L.P. Reduced· Q1 2026 −794K Q1 2026
5am Venture Management, LLC · Exited
Change −772K Δ Own −100.0% Date Q1 2026
5am Venture Management, LLC Exited· Q1 2026 −772K −100.0% Q1 2026
Siren, L.L.C. · New
Change +746K Date Q1 2026
Siren, L.L.C. New· Q1 2026 +746K Q1 2026
Alliancebernstein L.P. · Added
Change +735K Date Q1 2026
Alliancebernstein L.P. Added· Q1 2026 +735K Q1 2026
Baker Bros. Advisors LP · Added
Change +634K Date Q1 2026
Baker Bros. Advisors LP Added· Q1 2026 +634K Q1 2026
First Turn Management, LLC · New
Change +624K Date Q1 2026
First Turn Management, LLC New· Q1 2026 +624K Q1 2026
Data through Q1 2026 · filed Jun 4, 2026
15 of 171

Famous investor activity in Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics, Inc. (ELVN) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Hohl Benjamin · Officer 5 operations −$317K
Price $49.97–$53.87 Qty −6K Owned 46K ΔOwn −11.6% Trade date Jul 17, 2026 Filed date Jul 21, 2026
Hohl Benjamin Officer 5 operations $49.97–$53.87 −6K −$317K 46K −11.6% Jul 17, 2026 Jul 21, 2026
Hohl Benjamin · Officer 2 operations 0
Price $2.48 Owned 85K Trade date Jul 17, 2026 Filed date Jul 21, 2026
Hohl Benjamin Officer 2 operations $2.48 0 85K Jul 17, 2026 Jul 21, 2026
Collins Helen Louise · Officer 5 operations −$263K
Price $50.05–$53.92 Qty −5K Owned 25K ΔOwn −16.7% Trade date Jul 17, 2026 Filed date Jul 21, 2026
Collins Helen Louise Officer 5 operations $50.05–$53.92 −5K −$263K 25K −16.7% Jul 17, 2026 Jul 21, 2026
Collins Helen Louise · Officer 2 operations 0
Price $2.48 Owned 116K Trade date Jul 17, 2026 Filed date Jul 21, 2026
Collins Helen Louise Officer 2 operations $2.48 0 116K Jul 17, 2026 Jul 21, 2026
Kunkel Lori Anne · Director 2 operations −$505K
Price $49.98–$50.84 Qty −10K Owned 42K ΔOwn −19.3% Trade date Jul 6, 2026 Filed date Jul 8, 2026
Kunkel Lori Anne Director 2 operations $49.98–$50.84 −10K −$505K 42K −19.3% Jul 6, 2026 Jul 8, 2026
Orbimed Advisors LLC · 10% Owner 4 operations −$39M
Price $45.00–$45.38 Qty −860K Owned 6.6M Trade date Jun 22, 2026 Filed date Jun 24, 2026
Orbimed Advisors LLC 10% Owner 4 operations $45.00–$45.38 −860K −$39M 6.6M Jun 22, 2026 Jun 24, 2026
Hohl Benjamin · Officer 3 operations −$264K
Price $42.78–$44.75 Qty −6K Owned 51K ΔOwn −10.6% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Hohl Benjamin Officer 3 operations $42.78–$44.75 −6K −$264K 51K −10.6% Jun 17, 2026 Jun 22, 2026
Hohl Benjamin · Officer 2 operations 0
Price $2.48 Owned 86K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Hohl Benjamin Officer 2 operations $2.48 0 86K Jun 17, 2026 Jun 22, 2026
Collins Helen Louise · Officer 3 operations −$219K
Price $42.83–$44.74 Qty −5K Owned 25K ΔOwn −16.7% Trade date Jun 17, 2026 Filed date Jun 22, 2026
Collins Helen Louise Officer 3 operations $42.83–$44.74 −5K −$219K 25K −16.7% Jun 17, 2026 Jun 22, 2026
Collins Helen Louise · Officer 2 operations 0
Price $2.48 Owned 121K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Collins Helen Louise Officer 2 operations $2.48 0 121K Jun 17, 2026 Jun 22, 2026
Orbimed Advisors LLC · 10% Owner 2 operations −$13M
Price $45.02 Qty −281K Owned 7.4M Trade date Jun 15, 2026 Filed date Jun 17, 2026
Orbimed Advisors LLC 10% Owner 2 operations $45.02 −281K −$13M 7.4M Jun 15, 2026 Jun 17, 2026
Kunkel Lori Anne · Director 3 operations −$345K
Price $34.28–$35.82 Qty −10K Owned 52K Trade date Jun 5, 2026 Filed date Jun 9, 2026
Kunkel Lori Anne Director 3 operations $34.28–$35.82 −10K −$345K 52K Jun 5, 2026 Jun 9, 2026
Collins Helen Louise · Officer 3 operations −$199K
Price $39.53–$41.21 Qty −5K Owned 25K Trade date May 18, 2026 Filed date May 20, 2026
Collins Helen Louise Officer 3 operations $39.53–$41.21 −5K −$199K 25K May 18, 2026 May 20, 2026
Collins Helen Louise · Officer 2 operations 0
Price $2.48 Owned 126K Trade date May 18, 2026 Filed date May 20, 2026
Collins Helen Louise Officer 2 operations $2.48 0 126K May 18, 2026 May 20, 2026
Collins Helen Louise · Officer 3 operations −$238K
Price $45.81–$48.06 Qty −5K Owned 25K Trade date Apr 17, 2026 Filed date Apr 21, 2026
Collins Helen Louise Officer 3 operations $45.81–$48.06 −5K −$238K 25K Apr 17, 2026 Apr 21, 2026
15 of 78
15 of 78 Sign in to continue to older insider transactions.

Enliven Therapeutics, Inc. (ELVN) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Orbimed Advisors LLC 7.9M
% of shares outstanding 16.8% Filing date May 20, 2024
Orbimed Advisors LLC 7.9M 16.8% May 20, 2024
FMR LLC 5.9M
% of shares outstanding 14.3% Filing date Feb 9, 2024
FMR LLC 5.9M 14.3% Feb 9, 2024
Polar Capital Holdings PLC 5.1M
% of shares outstanding 8.5% Filing date Jun 22, 2026
Polar Capital Holdings PLC 5.1M 8.5% Jun 22, 2026
Commodore Capital LP 4.8M
% of shares outstanding 7.7% Filing date May 15, 2026
Commodore Capital LP 4.8M 7.7% May 15, 2026
Blackrock, Inc. 2.9M
% of shares outstanding 6.2% Filing date Nov 8, 2024
Blackrock, Inc. 2.9M 6.2% Nov 8, 2024
Vestal Point Capital, LP 3.2M
% of shares outstanding 5.4% Filing date May 15, 2026
Vestal Point Capital, LP 3.2M 5.4% May 15, 2026
5am Ventures Vi, L.P. 1.9M
% of shares outstanding 4.1% Filing date Jul 29, 2024
5am Ventures Vi, L.P. 1.9M 4.1% Jul 29, 2024
Citadel Advisors LLC 1.7M
% of shares outstanding 3.7% Filing date Nov 14, 2024
Citadel Advisors LLC 1.7M 3.7% Nov 14, 2024
8 of 13

Enliven Therapeutics, Inc. (ELVN) ownership FAQ

Who owns ELVN?

171 reporting institutions disclosed ELVN position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.